Biotechnology
Company Overview of GlycoRegImmune, Inc.
Company Overview
GlycoRegImmune, Inc., a biotech company, develops natural killer T (NKT) cells targeted therapies for liver disease, autoimmune disorders, and ischemic reperfusion injury. Its programs include NKT I cell inhibitors and NKT II cell modulators. The company is based in San Diego, California.
General Atomics Court
TPIMS
Suite 2-203
San Diego, CA 92121
United States
Key Executives for GlycoRegImmune, Inc.
GlycoRegImmune, Inc. Key Developments
GlycoRegImmune, Inc. Presents at 10th Annual BIO Investor Forum, Oct-25-2011 10:00 AM. Venue: Palace Hotel, 2 New Montgomery Street, San Francisco, California, United States.
RxMD, Inc., announced a collaboration agreement with GlycoRegImmune Inc. to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GlycoRegImmune Inc.'s novel natural killer T cell targeted technologies. Under the agreement, RxMD, Inc. will use its global drug development expertise, including its team of physician-scientists in Chennai, India, to advance GlycoRegImmune Inc.'s portfolio of drug candidates. The collaboration represents a new model for risk-sharing, success-based drug development.
Similar Private Companies By Industry
| Company Name | Region |
| Salvona Consumer Care, LLC | United States |
| Washington Biotechnology, Inc. | United States |
| Selectus Pharmaceuticals | United States |
| Alydar Pharmaceuticals Inc. | United States |
| BioConvergence LLC | United States |
Recent Private Companies Transactions
| Type Date |
Target | |
| No transactions available in the past 12 months. | ||
Most Searched Private Companies
| Company Name | Geographic Region |
| NYC2012, Inc. | United States |
| Bertelsmann AG | Europe |
| Lawyers Committee for Civil Rights Under Law | United States |
| Rush University | United States |
| Greater Houston Partnership | United States |
Post a JobJobs
- Boston, MA | PwCPosted: Aug 28
- Cambridge, MA | PfizerPosted: May 10
- Kennebunk, ME | CorningPosted: May 24
- San Francisco, CA | Confidential Biotechnology CompanyPosted: May 13
Sponsored Financial Commentaries
Sponsored Links
To contact GlycoRegImmune, Inc., please visit glycoregimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
